Zuckerman J N, Powell L, Lequin R M, Zuckerman A J
Academic Unit of Travel Medicine and Vaccines, Royal Free Hospital School of Medicine, London, UK.
J Virol Methods. 1996 Jan;56(1):27-31. doi: 10.1016/0166-0934(95)01898-0.
The quantitative responses to vaccination with hepatitis A vaccine was determined in 113 volunteers using a commercially available enzyme-linked immunosorbent assay for total antibodies to hepatitis A. Administration of vaccine or control preparation was carried out according to two regimens; at 0, 1 and 12 months (regimen I) and at 0, 0.5 and 12 months (regimen II). Seroconversion rates (concentrations of HAV antibodies > 50 IU/l) were between 94 and 97% at month 1 for regimen I and regimen II, respectively. The geometric mean titres (GMTs) fell gradually by month 12, and increased rapidly 10-100 fold 1 month after the booster dose at month 12. The GMTs of the groups receiving the control preparation remained below 50 IU/l. No significant differences were found between the antibody responses after regimen I or regimen II. It is concluded that the antibody test (Hepanostika HAV Antibody) can be used safely and adequately for quantitation of responses to hepatitis A immunisation.
使用市售的甲型肝炎总抗体酶联免疫吸附测定法,对113名志愿者接种甲型肝炎疫苗后的定量反应进行了测定。疫苗或对照制剂的接种按照两种方案进行:0、1和12个月(方案I)以及0、0.5和12个月(方案II)。方案I和方案II在第1个月时的血清转化率(甲型肝炎抗体浓度>50 IU/l)分别为94%至97%。几何平均滴度(GMT)在第12个月时逐渐下降,并在第12个月加强剂量后1个月迅速增加10至100倍。接受对照制剂组的GMT仍低于50 IU/l。方案I或方案II后的抗体反应之间未发现显著差异。结论是,抗体检测(Hepanostika HAV抗体)可安全、充分地用于定量甲型肝炎免疫反应。